Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-α) does not improve experimental autoimmune encephalomyelitis

Annals of Neurology

Volumn 47, Issue 1, 2000, Pages 127-131

  Brod, Staley A ^a,b   Lindsey, J William ^a   Wolinsky, Jerry S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ENCEPHALITOGENIC PROTEIN; GLATIRAMER; INTERFERON BETA SERINE; PROTEOLIPID; RECOMBINANT ALPHA2A INTERFERON;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; IMMUNOMODULATION; MOUSE; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE I; MICE; PEPTIDES;

EID: 0033960042     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200001)47:1<127::AID-ANA22>3.0.CO;2-1     Document Type: Article

References (19)

1. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant Interferon alpha-2a reduces exacerbation rate, MRI signs of activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413
2. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
3. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1994;39:285-294
4. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504
5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276
6. Myhr KM, Riise T, Green Lilleas FE, et al. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 1999;52:1049-1056
7. Lublin FD, Reingold SC. Combination therapy for treatment of multiple sclerosis [see comments]. Ann Neurol 1998;44:7-9 (Editorial)
8. Alvord EC, Shaw CM, Huby S, Kies MK. Encephalitogeninduced inhibition of experimental allergic encephalomyelitis: prevention, suppression, and therapy. Ann NY Acad Sci 1965; 122:333-345
9. Brod SA. Effect of oral administration of type 1 interferon on experimental autoimmune encephalomyelitis. In: Reder AT, ed. Interferon therapy in multiple sclerosis. New York, Marcel Dekker, 1996:245-286
10. Brod SA, Khan M. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun 1996;9:11-20
11. Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 1979;123:2156-2160
12. Lisak RP, Zweiman B, Blanchard N, Rorke EB. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE). J Neural Sci 1983;62:281-293
13. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 1998;9:135-146
14. Teitelbaum D, Aharoni R, Arnon R, Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci USA 1988;85: 9724-9728
15. Abreu SL. Suppression of experimental allergic encephalomyelitis by interferon. Immunol Commun 1982;11:1-7
16. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996;64:91-100
17. Stuve O, Dooley N, Uhm H, et al. IFNβ-1b decreases the migration of T lymphocytes in vitro-effects on matrix metalloproteinase-9. Ann Neural 1996;40:853-863
18. Ito S, Ansari P, Sakatsume M, et al. Interleukin-10 inhibits expression of both interferon alpha-and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999;93:1456-1463
19. Larner AC, Petricoin EF, Nakagawa Y, Finbloom DS. IE-4 attenuates the transcriptional activation of both IFN-alpha and IFN-gamma-induced cellular gene expression in monocytes and monocytic cell lines. J Immunol 1993;150:1944-1950